Can Lab-Tested tumor fragments pick the right drug for stubborn cancers?

NCT ID NCT07264803

Recruiting now Knowledge-focused Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new method to help choose cancer drugs for people with hard-to-treat solid tumors. Doctors take a small piece of the tumor, grow it in the lab, and test many drugs on it to see which works best. Then they give that drug to the patient. The goal is to see if this approach leads to tumor shrinkage in 35 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient-derived tumor tissue fragment (PDTF) drug sensitivity testing
What this could lead to: If successful, this could provide a faster, more reliable way to choose effective drugs for patients with cancers that have stopped responding to standard treatments.
What could go wrong: This is a small, early-phase exploratory study (35 people) without a control group. The approach may not improve outcomes for all patients, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer gastric cancer gastroesophageal junction adenocarcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR CANCER SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Qilu Hospital of Shandong Univertisy
RECRUITING

Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.